CrystalPharma and Divamics Bio Forge Strategic 'AI + Experiment' Partnership to Overcome the 'Three Tens' Challenge in Drug Discovery
Divamics
AI Drug Discovery Platform
Against the backdrop of high costs and long cycles in innovative drug development, Divamics and CRYSTAL Pharmatech are leveraging cutting-edge technologies to focus on key aspects of the drug discovery process:
Divamics: Relying onArtificial Intelligence (AI), Quantum Chemistry Computing, and Molecular Dynamics Simulation Patent TechnologyFocused on the efficient design and optimization of new drug molecules. Its computational chemistry platform can rapidly generate active and drug-like molecular structures, significantly shortening the traditional drug discovery cycle and reducing early R&D trial-and-error costs. Applicable fields include small molecules, peptides, antibodies, PROTACs, enzymes, etc. Currently, two collaborative pipelines have successfully advanced to Phase III clinical trials.
CRYSTAL Pharmatech: CRYSTAL Pharmatech focuses on providingOptimal Crystal Form and Formulation SolutionsBy optimizing crystal forms and formulation technologies, the developability of new drugs is significantly enhanced, accelerating their clinical progress and commercialization. CRYSTAL Pharmatech's services cover: Mol2Med developability assessment, screening and determination of drug crystal forms, salts, and co-crystals, crystallization process development, preclinical formulation research, and optimal formulation development, production, and clinical supply for Phase I, II, III, and commercial stages.
Both CRYSTAL Pharmatech and Divamics Inc. have deep expertise in their specialized niche fields and are committed to becoming "hidden champions" in their respective domains. Through this strategic collaboration, the two parties will establish a critical pathway encompassing “molecular design-polymorph formulation-clinical supply,” providing pharmaceutical companies with more efficient and reliable R&D support.
This strategic cooperation is not only a complementary advantage between two technology-driven enterprises but also an upgrade to the paradigm of new drug research and development. Through the deep integration of AI and experimental science, more molecules with high development potential will be moved to clinical trials faster in the future, benefiting patients worldwide.
Dr. Zheng Zheng, Founder of Divamics"It is stated that: 'The cooperation with CRYSTAL Pharmatech is a model of ‘AI + experimental science.’ We look forward to leveraging Divamics' patented AI and computational chemistry technologies to rationally design at the molecular level, effectively, accurately, and rapidly advancing the drug pipeline to PCC and delivering it. Combined with CRYSTAL Pharmatech's profound expertise in crystal form formulation, we will jointly provide the industry with an integrated one-stop drug R&D solution that combines dry and wet experiments.'"
Dr. Minhua Chen, Co-founder, Chairman and CEO of CRYSTAL Pharmatech"Divamics' AI technology can significantly improve the efficiency of drug discovery, while CRYSTAL Pharmatech's core technology ensures these molecules are quickly transformed into developable drugs. The collaboration between the two parties will greatly shorten the 'valley of death' phase in new drug development."
For more information, please visit
About Divamics
Divamics is a company thatArtificial Intelligence, Quantum Mechanics, and Molecular Simulation AlgorithmsA technology-driven biopharmaceutical company powered by core technologies and cross-disciplinary techniques to simulate and empower new drug research and development. The company is based onA Next-Generation AI Drug Discovery Platform Built by Combining Multiscale Molecular Dynamics with Self-Innovated AI Algorithms, providing a variety of computational chemistry services, including but not limited to highly flexible target modeling, target druggability analysis, drug screening, design, and optimization for small molecules, peptides, antibodies, PROTACs, and other fields. Particularly for difficult-to-drug targets, we offer molecular druggability mechanism analysis, novel drug molecular structure design, and structural optimization solutions.
The company has been awarded the Suzhou Industrial Park Technology Leading Project, the Suzhou-level Gusu Leading Talent Project, and the National High-tech Enterprise. Its core technology has been recommended by Professor Roald Hoffmann, a Nobel Prize winner in Chemistry. The company's headquarters is located in Suzhou, with a computing center in Beijing and BD cooperation centers in Singapore and Japan. It has currently collaborated with over 40 domestic and international biopharmaceutical companies to advance more than 70 new drug development pipelines. On average, it takes about 30 molecules and half a year to one year to successfully advance to PCC, significantly revolutionizing the traditional "three tens" dilemma of long new drug molecule R&D cycles, high costs, and low success rates. Two collaborative pipelines have successfully entered Phase III clinical trials.
About CRYSTAL Pharmatech
CRYSTAL Pharmatech is aCRO/CDMO Driven by Technology as the CoreEnterprise, Focused onResearch on Polymorphs of Small Molecule Drugs、Formulation Development and Manufacturing、Clinical Supply Services, andBioanalysisAndLarge Molecule CMC Analysis...and other细分领域. CRYSTAL Pharmatech is committed to providing high-quality, customized technical solutions for global innovative drug research and development, accelerating the entire process from preclinical to Phase I clinical trials and commercialization, significantly enhancing drug competitiveness and maximizing its commercial value. With its excellent technical services, CRYSTAL Pharmatech has become the preferred partner for new drug clients in its focused细分领域.
Since its establishment in 2010, CRYSTAL Pharmatech has built a solid business presence in both China and North America, with R&D and production centers located in Suzhou, China; New Jersey and the San Francisco Bay Area in the United States; and Toronto, Canada. The company boasts a professional team of nearly 300 employees. Leveraging innovative technology and deep scientific expertise, CRYSTAL Pharmatech has collaborated with more than1000Cooperation with a pharmaceutical company in China has successfully supported2000Multiple new drug projects accelerate the launch of innovative drugs, benefiting patients worldwide.
http://www.crystalpharmatech.com.cn
contact@crystalpharmatech.com
Crystal Building · No. 288, Jiangyun Road, Suzhou Industrial Park